Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | SLC6A7 | Q99884 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12822619 | 0.93 | PARP1 (0.54) | PARP1KDM4ECYP3A4CYP1A2CYP2D6 | |
| SCHEMBL15420546 | 0.90 | PARP1 (0.54) | PARP1KDM4ESMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL15420958 | 0.90 | PARP1 (0.54) | PARP1KDM4ESMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL30428120 | 0.90 | PARP1 (0.54) | PARP1KDM4ESMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL30418027 | 0.89 | PARP1 (0.61) | PARP1KDM4EPTGS1PTGS2ALDH1A1 | |
| SCHEMBL12821925 | 0.89 | PARP1 (0.61) | PARP1KDM4EPTGS1PTGS2ALDH1A1 | |
| SCHEMBL29722532 | 0.89 | HDAC1 (0.54) | PARP1KDM4ECYP2C9SMN1; SMN2HDAC1 | |
| SCHEMBL12822263 | 0.89 | HDAC1 (0.54) | PARP1KDM4ECYP2C9SMN1; SMN2HDAC1 | |
| Hydrochloric Acid SCHEMBL15420661 | 0.88 | PARP1 (0.61) | PARP1KDM4EPTGS1PTGS2ALDH1A1 | |
| SCHEMBL12822699 | 0.87 | ALDH1A1 (0.60) | PARP1KDM4ECYP3A4CYP2D6SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230263801-A1 | COMBINATION THERAPY OF PARP INHIBITORS | Impact Therapeutics (Shanghai), Inc (CN) | 2023-08-24 | — | — | US | claimed |
| US-11358955-B2 | 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof | IMPACT THERAPEUTICS, INC. (CN) | 2022-06-14 | — | — | US | claimed |
| US-20190270732-A1 | 1-(Arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP Inhibitors and the Use Thereof | IMPACT THERAPEUTICS, INC. (CN) | 2019-09-05 | — | — | US | claimed |
| EP-2709990-B1 | 1-((3-((1-Piperazinyl)carbonyl)phenyl)methyl)-2,4(1H,3H)-quinazolinedione derivatives as PARP inhibitors for treating cancer | IMPACT THERAPEUTICS INC (CN) | 2019-06-12 | — | — | EP | claimed |
| US-20140023642-A1 | 1-(Arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP Inhibitors and the Use Thereof | IMPACT THERAPEUTICS, INC. (CN) | 2014-01-23 | — | — | US | claimed |
| US-20230263801-A1 | COMBINATION THERAPY OF PARP INHIBITORS | Impact Therapeutics (Shanghai), Inc (CN) | 2023-08-24 | — | — | US | disclosed |
| US-11358955-B2 | 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof | IMPACT THERAPEUTICS, INC. (CN) | 2022-06-14 | — | — | US | disclosed |
| US-20190270732-A1 | 1-(Arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP Inhibitors and the Use Thereof | IMPACT THERAPEUTICS, INC. (CN) | 2019-09-05 | — | — | US | disclosed |
| EP-2709990-B1 | 1-((3-((1-Piperazinyl)carbonyl)phenyl)methyl)-2,4(1H,3H)-quinazolinedione derivatives as PARP inhibitors for treating cancer | IMPACT THERAPEUTICS INC (CN) | 2019-06-12 | — | — | EP | disclosed |
| US-10316027-B2 | 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof | IMPACT THERAPEUTICS, INC. (CN) | 2019-06-11 | — | — | US | disclosed |
| US-20180215741-A1 | 1-(Arylmethyl)quinazoline-2,4(1H,3H)-Diones as PARP Inhibitors and the Use Thereof | IMPACT THERAPEUTICS INC (CN) | 2018-08-02 | — | — | US | disclosed |
| US-9926304-B2 | 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof | IMPACT THERAPEUTICS, INC. (CN) | 2018-03-27 | — | — | US | disclosed |
| US-20160237070-A1 | 1-(Arylmethyl)quinazoline-2,4(1H,3H)-Diones as PARP Inhibitors and the Use Thereof | IMPACT THERAPEUTICS, INC. (CN) | 2016-08-18 | — | — | US | disclosed |
| US-9290460-B2 | 1-(Arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof | IMPACT THERAPEUTICS, INC. (CN) | 2016-03-22 | — | — | US | disclosed |
| EP-2709990-A1 | 1-(ARYLMETHYL)QUINAZOLINE-2,4(1H,3H)-DIONES AS PARP INHIBITORS AND THE USE THEREOF | Impact Therapeutics, Inc. (CN) | 2014-03-26 | — | — | EP | disclosed |
| US-20140023642-A1 | 1-(Arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP Inhibitors and the Use Thereof | IMPACT THERAPEUTICS, INC. (CN) | 2014-01-23 | — | — | US | disclosed |
| WO-2012130166-A1 | 1-(ARYLMETHYL)QUINAZOLINE-2,4(1H,3H)-DIONES AS PARP INHIBITORS AND THE USE THEREOF | IMPACT THERAPEUTICS, INC. (CN) | 2012-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270732-A1 | 1-(Arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP Inhibitors and the Use Thereof | PARP1, PARP11, PARP3 | PARP1 1/4885KDM4E 737/4885CYP3A4 727/4885 |
| US-20230263801-A1 | COMBINATION THERAPY OF PARP INHIBITORS | PARP2, PARP1, PARP3 | PARP1 2/4885KDM4E 1340/4885CYP3A4 1904/4885 |
| US-10316027-B2 | 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof | PARP1, PARP11, PARP3 | PARP1 1/4885KDM4E 704/4885CYP3A4 797/4885 |
| US-20160237070-A1 | 1-(Arylmethyl)quinazoline-2,4(1H,3H)-Diones as PARP Inhibitors and the Use Thereof | PARP1, PARP11, PARP3 | PARP1 1/4885KDM4E 737/4885CYP3A4 727/4885 |
| US-20180215741-A1 | 1-(Arylmethyl)quinazoline-2,4(1H,3H)-Diones as PARP Inhibitors and the Use Thereof | PARP1, PARP11, PARP3 | PARP1 1/4885KDM4E 704/4885CYP3A4 797/4885 |
| US-11358955-B2 | 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof | PARP1, PARP11, PARP3 | PARP1 1/4885KDM4E 737/4885CYP3A4 727/4885 |
| US-20140023642-A1 | 1-(Arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP Inhibitors and the Use Thereof | PARP1, PARP11, PARP3 | PARP1 1/4885KDM4E 617/4885CYP3A4 751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.